Figure 2
The response to STING agonist in PDAC of KPC mice. (a) IHC analysis of STING (upper) and phospho-STING (lower) in PDACs of KPC mice with or without the STING agonist DMXAA (5,6-dimethyl-9-oxo-9H-xanthene-4-acetic acid) (scale bar, 100 μm). (b) Fold changes of the mRNA levels of the indicated cytokines and chemokines in DMXAA-treated PDACs relative to the mean of the control tumor (N = 4). DMXAA or vehicle was administered to 15-week-old KPC mice on days 1, 4, and 7, and the mice were dissected 2 h after the final dose. Data are graphed on a log-scale. (*P < 0.05) Each dot indicates a measure, and the bars indicate the mean. (c) IHC analysis of CD8a and Cleaved caspase-3 in vehicle- or DMXAA-treated mice. DMXAA was administered as described in (b) (scale bar, 250 μm (upper), 100 μm (lower)). (d) Ratio of CD8a-positive area per mouse and number of cleaved caspase-3-positive cells per field per mouse. Each dot indicates a measure, and the bars indicate the mean. (e) Fold change of granzyme B and perforin mRNA levels in DMXAA-treated PDACs relative to the mean of the control tumor (N = 3). DMXAA was administered 2 days prior to dissection (*P < 0.05). Each dot indicates a measure, and the bars indicate the mean.
